🇨🇦 Canada Health Canada

Retatrutide

Triple GLP-1/GIP/glucagon receptor agonist — next-generation metabolic research compound

Phase 3 available Health Canada
Key stats Research
Triple
Receptor agonist (GLP-1/GIP/glucagon)
Phase 3
Current clinical trial stage
24.2%
Max body weight reduction (Phase 2, 48wk)
Eli Lilly
Developer
🇨🇦 Canada Health Canada

Mechanism

What is Retatrutide?

Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials. It has shown significant weight loss results — up to 24% body weight reduction in Phase 2 trials.

🇨🇦 Canada · Health Canada

Legal status

🇨🇦 Canada — Health Canada
available

Retatrutide has not received Health Canada approval for therapeutic use. Not a controlled substance under Canadian scheduling. Legal to import for research purposes.

This website is intended for research and educational purposes only. The information provided does not constitute medical advice and should not be used to diagnose, treat, cure, or prevent any condition. Peptides discussed on this site are not approved by Health Canada for human therapeutic use. Always consult a qualified healthcare professional before using any substance.

Full legal guide for Canada →

Frequently asked

Common questions

Is retatrutide legal in Canada?

Retatrutide is not approved by Health Canada for therapeutic use and is not a controlled substance. It can be imported for legitimate research purposes.

Can I buy retatrutide in Canada?

Research-grade retatrutide is available from international vendors that ship to Canada. It is not available from Canadian pharmacies as a therapeutic medicine.

Where to source Retatrutide

Retatrutide in Canada

We verify COA documentation and purity standards before listing any vendor.

Get vendor access →